Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 8/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830387 | 1.00 | DAO (0.36) | DAONFE2L2AHRKDM4ENPC1 | |
| SCHEMBL831069 | 1.00 | DAO (0.36) | DAONFE2L2AHRKDM4ENPC1 | |
| SCHEMBL830616 | 0.85 | KMT2A (0.37) | NFE2L2KDM4ENPC1MAPTRAB9A | |
| SCHEMBL830507 | 0.85 | KMT2A (0.37) | NFE2L2KDM4ENPC1MAPTRAB9A | |
| SCHEMBL830506 | 0.85 | KMT2A (0.37) | NFE2L2KDM4ENPC1MAPTRAB9A | |
| SCHEMBL830382 | 0.85 | PIM1 (0.42) | NFE2L2AHRPTGES2 | |
| SCHEMBL831859 | 0.85 | PIM1 (0.42) | NFE2L2AHRPTGES2 | |
| SCHEMBL830383 | 0.85 | PIM1 (0.42) | NFE2L2AHRPTGES2 | |
| SCHEMBL830471 | 0.77 | DAO (0.48) | DAONFE2L2AHRKDM4ENPC1 | |
| SCHEMBL830949 | 0.77 | DAO (0.48) | DAONFE2L2AHRKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | claimed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | claimed |
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | DAO 3359/4885NFE2L2 1235/4885AHR 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.